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Abstract
Background: To explore the anti-tumor effects of parthenolide in human pancreatic cancer.
Methods: BxPC-3 cell, a human pancreatic cancer, was treated with parthenolide at different concentrations. The
MTT assay was used to analyze cell viability. Flow cytometry and DNA fragmentation analysis were applied to
evaluate apoptosis after parthenolide treatment. The wound closure and cell invasion assay were also employed in
the study. Western blotting was used to demonstrate Bad, Bcl-2, Bax, caspase-9 and pro-caspase-3 expression.
Results: The MTT assay indicated that the pancreatic cancer growth could be dose-dependently inhibited by
parthenoolide. This phenomenon was confirmed by flow cytometry and DNA fragmentation analysis. The wound
closure assay and cell invasion assay showed that BxPC-3 cell was significantly suppressed by parthenolide at
7.5 μM and 15 μM. Western Blotting demonstrated the Bcl-2 and pro-caspase-3 were down-regulated while the
Bax and caspase-9 were up-regulated. No alteration in Bad expression was found after treatment.
Conclusions: The parthenolide can inhibit the cell growth, migration, and induce the apoptosis in human
pancreatic cancer. These findings may provide a novel approach for pancreatic cancer treatment.
Background
Pancreatic adenocarcinoma is among the leading causes
of cancer related mortality throughout the world [1].
Currently surgical resection is still the main therapeutic
approach. However most cases are unresectable when
diagnosed. Even in resectable cases, the long-term out-
come remains unsatisfactory. The statistics disclosed
that one-year survival rate was less than 10%, 5-year
survival rate was less than 1% and median survival dura-
tion ranged from three to four months, respectively.
T h ec l i n i cr e a l i t ym e n t i o n e da b o v em a d ec h e m o t h e r a p y
essential for a cure. However drug-resistance can com-
promise the therapeutic effectiveness which is the major
concern nowadays [2].
Parthenolide (PTL) is the main extracts of sesquiter-
pene lactone isolated from Mexican and Indian herbs
such as feverfew (Tanacetum parthenium). PTL has been
used conventionally to treat migraine and rheumatoid
arthritis for centuries [3]. Recently it has been reported
that PTL may induce inhibition of proliferation and
apoptosis in various human cancer cells in vitro, such as
colorectal cancer, hepatoma, cholangiocarcinoma [4-6]. In
addition, PTL can sensitize resistant cancer cells to anti-
tumor agents [7,8] and act as a chemo-preventive agent
in an animal model of UVB-induced skin cancer [9].
Meanwhile data have showed that PTL-induced apoptosis
is associated with inhibition of transcription factor
nuclear factor-kappa B (NF-kB) [3,10], mitochondrial dys-
function and increase of reactive oxygen [11,12]. However
the detailed molecular mechanisms of anticancer effect of
PTL are largely unknown.
Our study disclosed that PTL induced apoptosis in
BxPC-3 cells mainly by influencing bcl-2 family. PTL
and its sesquiterpene lactone analogues might be new
chemotherapeutic agents for pancreatic cancer.
Methods
Cell culture and reagents
Human pancreatic cancer cell line BxPC-3 was pur-
chased from Shanghai Institute of Cell Biology, Chinese
Academy of Sciences (Shanghai, China). It was cultured
in dulbecco’s modified eagle’sm e d i u m( D M E M ,
HyClone, Logan, Utah, USA) containing 10% fetal
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peniciline streptomycin mixture at 37°C in a humidified
atmosphere of 5% CO2 and 95% air. Parthenolide
(Sigma, St. Louis, MO, USA) supplied as a crystalline
solid was dissolved in dimethylsulfoxide (100 mM stock)
and stored at -20°C. Antibodies used in this study were
obtained from Santa Cruz (CA, USA) and Cell Signaling
Technology (CA, USA) respectively.
MTT colorimetric survival assay
BxPC-3 cells were plated at a density of 1.0 × 10
4 cells
p e rw e l li n9 6w e l lp l a t e s .2 4h o u r sa f t e ri n c u b a t i o n ,
cells were treated by PTL at indicated concentrations
for 48 hours; then the medium was removed and 200 μl
of fresh medium plus 20 μl of 3-(4, 5-dimethylthiazol-
2yl)-2, 5-diphenyltetrazolium bromide (MTT, 2.5 mg
dissolved in 50 μl of dimethylsulfoxide, Sigma, St. Louis,
MO, USA) were added to each well. After incubation
for 4 hours at 37°C, the culture medium containing
MTT was withdrawn and 200 μl of dimethylsulfoxide
(DMSO) was added, followed by shaking for 10 minutes
until the crystals were dissolved. Viable cells were
detected by measuring absorbance at 570 nm using
MRX II absorbance reader (DYNEX Technologies,
Chantilly, Virginia, USA). The cell growth was expressed
as a percentage of absorbance in cells with PTL treat-
ment to that in cells without PTL treatment (100%).
The inhibition rate (IR) was calculated as follows: IR =
(1-A value of PTL well/A value of control well) × 100%
Flow Cytometry
1×1 0
5 cells suspended in 2 ml fresh media were plated
in each well of a 6-well flat-bottomed microtiter plate
and incubated overnight. Then PTL with indicated con-
centrations were added. After 48 hours cells were har-
vested and washed twice with pre-cold PBS and then
resuspended in 1× binding buffer at a concentration of
1×1 0
6 cells/ml. 100 μl of such solution (1 × 10
5 cells)
was mixed with 5 μl of annexin V-FITC and 5 μl of Pro-
pidium Iodide (PI) (BD Biosciences, San Jose, CA, USA)
according to the manufacturer’s introduction. The
mixed solution was incubated at room temperature (25°
C) away from light for 15 minutes. Then 400 μlo f1 ×
dilution buffer was added to each tube. Analysis was
performed by Beckman Coulter FC500 Flow Cytometry
System with CXP Software (Beckman Coulter, Fullerton,
CA, USA) within 1 hour.
DNA fragmentation analysis
BxPC-3 cells (1 × 10
6 cells) were seeded in 6-well
microtiter plate. Then the cells were treated with the
indicated concentrations of PTL for 48 hours. For analy-
sis of genomic DNA, attached and nonattached cells in
the supernatant were harvested and collected together.
DNA was extracted by the DNA extraction kit (QIA-
GEN, German) according to the manufacturer’s instruc-
tion. 5 μg of DNA was separated on a 2% agarose gel.
DNA in the gel was stained with ethidium bromide,
visualized under UV light, and photographed.
Wound closure assay
Cells were plated in 6-well-plates. When the cells grew
into full confluency, a wound was created on the mono-
layer cells by scraping a gap using a micropipette tip
and then PTL with indicated concentrations were added
immediately after wound creation. The speed of wound
closure was compared between PTL treated groups and
the control group (PTL untreated cells). Photographs
were taken under 100× magnifications using phase-
contrast microscopy (OLYMPUS IX70, Olympus, Tokyo,
Japan) immediately after wound incision and at later
time points as showed.
Cell invasion assay
A Transwell cell culture chamber (Millipore, Bedford,
MA, USA) with a 6.5-mm-diameter polycarbonate filters
(8-μm pore size) was coated with Matrigel, dried and
reconstituted at 37°C with culture medium. Cells were
divided into three groups: the control group, 7.5 μM
group and 15 μM PTL group. We placed culture med-
ium containing 20% FBS in the lower chamber (24-well-
plates). Then the cells at 1 × 10
5 cells per chamber were
added to the upper chamber in DMEM containing 10%
FBS. After 48 hours incubation at 37°C the suspended
media in the lower chamber were removed. The cells
that had invaded to the lower side of the filter were
fixed in methanol, stained with GIMSA solution. The
number of cells that passed through the pores into the
lower chamber was counted under a phase-contrast
microscope (Leica DMLB2, Leica Microsystems AG,
Wetzlar, Germany) (five fields per chamber).
Western blotting
Proteins were extracted from cultured cells and were sub-
jected to western blot analysis using specific antibodies
for bcl-2, caspase-9 and pro-caspase-3 protein. The cells
(~2 × 10
8 cells) were harvested and rinsed twice with
PBS after PTL treatment for 48 hours. Cell extracts were
prepared with pre-cold lysis buffer (50 mM Tris-HCl,
150 mM NaCl, 1% Triton X-100, 0.5% deoxycholate,
1 mM EDTA, 1 mM Na3VO4, 1 mM NaF, 2% Cocktail)
and cleared by centrifugation at 12000g for 30 minutes at
4°C. Total protein concentration was measured using the
BCA assay kit (Sigma) according to the manufacturer’s
instruction. Cell extracts containing 30 μgo ft o t a lp r o t e i n
were separated by 12% SDS-polyacrylamide gel electro-
phoresis (SDS-PAGE), and the proteins were electrotrans-
ferred onto nitrocellulose membrane (Millipore, Bedford,
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(10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween-
20) containing 5% w/v nonfat milk, and then incubated
with primary antibody (dilution factor, 1:1000) in TBST
with gentle agitation overnight at 4°C. The membrane
was washed 3 times for 10 minutes incubation with
TBST and hybridized with redish-peroxidase (HRP)-
conjugated secondary antibody (1:2000 dilution, Dakocy-
tomation corporation, Glostrup, Denmark) corresponding
to each primary antibody with gentle agitation for
2 hours at room temperature. Protein bands specific for
antibody were visualized by enhanced chemiluminescence
(Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Statistical analysis
All the detection items in this study were repeated at
least 3 times. Statistical analysis was done using SPSS
software (Version 13.0, SPSS Inc, Chicago, IL, USA).
The data was expressed as mean ± SD. Statistical signifi-
cance of the differences between the control- and PTL-
treated cells was determined by a two-tailed Student’st
test with a 95% confidence interval.
Results
PTL inhibited proliferation of the pancreatic cancer cell in
a dose-dependent manner
The survival and inhibition rate of BxPC-3 cells follow-
ing treatment with different PTL concentrations was
measured. Cells treated with PTL for 48 hours were
compared with PTL-untreated cells. The MTT assay
(Fig. 1) demonstrated that treatment with 1 μMa n d2
μM for 48 hours insignificantly triggered cell death (P >
0.05 VS control). However, concentrations from 5 μM
to 30 μM could markedly inhibit tumor cells (P < 0.01
VS control). The bivariate correlation analysis confirmed
the negative relationship between PTL concentrations
and cell survival rates and the positive relationship
between PTL concentrations and cell inhibition rates. In
BxPC-3 cells, EC50 was estimated to be 14.5 μM.
PTL induced significant apoptosis in human pancreatic
cancer cell
To investigate the effect of inducting apoptosis by PTL
in BxPC-3 cells, the flow cytometry and DNA fragmen-
tation analysis were preformed. Annexin-V/PI-FACS
analysis (Fig. 2A) was applied to quantify the apoptotic
phenotype. Annexin-V-positive cells (right quadrant in
the density dot plot) were summarized, including early
apoptotic and late apoptotic cell death. PTL-treated
cells revealed morphologic events of apoptosis more sig-
nificantly than cells treated with DMSO alone. The
inductive effect of apoptosis presented as a concentra-
tion-dependent manner. The apoptosis induced was
further confirmed using DNA fragmentation analysis
(Fig. 2B). Disintegrated nuclei and nonrandom DNA
fragmentation were found on gels. More apoptotic inter-
nucleosomal DNA fragmentation was observed after
higher concentrations of PTL treatment. These results
revealed that PTL effectively induced a dose-dependent
apoptosis in human pancreatic cancer cell.
PTL suppressed BxPC-3 cell migration
Increased migration rate is one of the characteristics in
metastatic cancer cells [13]. Pancreatic cancer is a major
health problem due to its high risk of metastasis. Accord-
ingly the wound closure assay (Fig. 3) was used to investi-
gate if PTL influenced migration ability of BxPC-3 cells.
Wound gap of similar size was created in monolayer
BxPC-3 cells at 0 hour. The gap was filled with migrating
cells gradually and nearly closed in the control group
after 24 hours. Oppositely, the wounds were still widely
open at 24 hours after exposure to PTL at indicated con-
centrations. The results indicated that PTL treatment
could inhibit migration of pancreatic cancer cell.
PTL inhibited BxPC-3 cell invasion
The effect of PTL on BxPC-3 cell invasion was detected by
a reconsitituted Matrigel membrane. The number of cells
Figure 1 PTL inhibited BxPC-3 proliferation. MTT assay
demonstrated that PTL can inhibit BxPC-3 cell growth in vitro.
Besides, this effect was in a dose-dependent manner. The cell
viability and inhibition rates were calculated by comparing with the
control group (100%) after 48 hours treatment. Data were presented
as mean ± SD (n = 3). Points, mean; bars, + SD. *, P > 0.05; **, P <
0.01 compared with the control group.
Liu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:108
http://www.jeccr.com/content/29/1/108
Page 3 of 7that passed through the filter and into the lower chamber
was counted and compared. As a result, PTL at different
concentrations obviously inhibited invasive ability of pan-
creatic cancer cell. The cell numbers of 7.5 μMa n d1 5
μM PTL groups were (94 ± 7)/HPF and (58 ± 8)/HPF
respectively, which were less than (146 ± 10)/HPF of con-
trol group (P < 0.05) (Fig. 4).
PTL downregulated Bcl-2 and upregulated Bax
expression. No change was found on Bad
The underlying mechanism of PTL was also explored in
the study. The activation of several apoptosis-related
proteins may contribute to PTL-induced apoptosis. In
Bcl-2 family members, the expression of Bcl-2, Bax and
Figure 2 PTL induced BxPC-3 apoptosis. BxPC-3 cells were treated with the indicated concentrations of PTL for 48 hours. (A) The
quantification of apoptosis was estimated by Annexin-V/PI-FACS analysis. As apoptotic events Annexin-V-positive cells (right quadrant in the
density dot plot) were summarized. (B) DNA Fragmentation Analysis indicated that the cells treated with higher concentrations of PTL showed
higher proportions of apoptotic internucleosomal DNA fragmentation. These results revealed that PTL-induced apoptosis in BxPC-3 cells was in a
dose-dependent manner. The data was described as mean ± SD (n = 3) and the representative figures are shown.
Figure 3 PTL suppressed BxPC-3 migration. The wound gap of
cells was scratched by a micropipette tip. Cells were incubated in
the presence of PTL. 24 hours later the wound gap of BxPC-3 in the
control group was nearly closed. On the contrary, after exposure to
PTL at 7.5 μM, the speed of wound closure was much slower and
the wound was still widely open at twenty-four hours.
Figure 4 PTL inhibited BxPC-3 cells invasion.C e l l sw e r ef i x e d ,
stained and counted at 48 hours. The invasion cell numbers in PTL-
treated groups were significantly less than the control group (P <
0.05), which indicated that PTL suppressed cell invasion dose-
dependently.
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Western blotting (Fig. 5A). PTL obviously decreased the
p r o t e i ne x p r e s s i o no fa n t i a p o ptotic Bcl-2 and increased
the protein expression of proapoptotic Bax in the BxPC-
3 cells after being treated with indicated concentrations.
No change was found on Bad. Therefore, the suscept-
ibility to PTL-induced apoptosis might be attributable to
the imbalance of Bcl-2/Bax (Fig. 5B).
Effect of PTL at various concentrations on caspase-9 and
caspase-3 expression
Data have showed many anticancer agents are capable
of initiating the caspase activation and inducing
apoptosis [14]. Hence the caspase cascade in PTL-
induced effect was also analyzed. After PTL treatment at
indicated concentrations for 48 hours, Caspase-9 and
Pro-caspase-3 expressions of BxPC-3 cell were explored
(Fig. 5C). The dose-dependent proteolytic cleavage of
caspase-9 was detected. Following caspase-9 activation,
Pro-caspase-3 expression was downregulated signifi-
cantly. Therefore, PTL-induced apoptosis was confirmed
to be caspase-dependent.
Discussion
Pancreatic cancer is a major unsolved health problem
because of its biological aggressiveness. In the last dec-
ade, traditional clinical cancer therapy regimens as sur-
gical tumor resection, cytotoxic chemotherapy, and
radiation therapy have been supplemented with indivi-
dualized targeted therapies directed against molecular
determinants of the tumor. In spite of improved multi-
modal therapeutic regimens, 5 year survival does not
exceed 5 percent. Inherent or acquired resistance
towards cytotoxic agents, ionizing radiation, or both, is
one of the hallmarks of biological aggressiveness of pan-
creas cancer as a solid tumor. To develop a new che-
motherapeutic agent is still a clinical major concern as
well as the better understanding of etiopathogenesis and
molecular biology of pancreatic cancer.
NF-kB is ubiquitous and can be detected in the cyto-
plasm of many cell types. Several researches have indi-
cated that constitutive NF-kB activation may conduce to
pancreatic tumorigenesis [15,16]. Hence, the chemother-
apeutic potential of NF-kB inhibitors should be evalu-
ated. PTL is one of the traditional medicines extracted
from medical herb Feverfew in European and American.
Studies have shown that PTL targets NF-kB via inhibi-
tion of the upstream regulator IkB kinase (IKK) [17]
which phosphorylates IkB and targets it for proteasomal
degradation. PTL and its analogues have recently been
shown to inhibit proliferation, suppress invasiveness and
induce apoptosis of several human cancer cells [4-6,18].
Further studies indicate that in vitro and vivo PTL and
its analogues-induced growth inhibition and apoptosis is
associated with NF-kB pathway, and the effect is more
significant combined with COX inhibitor [12,19]. But
the detailed and precise mechanism underlying PTL
induced apoptosis remains unclear which attracted our
interest.
In our study it was found that PTL significantly inhib-
ited growth of BxPC-3 cells. MTT assay demonstrated a
dramatic loss of viability of cancer cell which was treated
with PTL in a dose-dependent fashion. Next PTL-
induced apoptosis was observed. Flow cytometry indi-
cated that PTL conspicuously induced apoptosis which
was confirmed by DNA fragmentation analysis. Mean-
while the migration and invasion assay indicated that
Figure 5 Apoptosis-related protein expression after PTL
treatment for 48 hours. (A) PTL decreased Bcl-2 expression and
induced Bax expression. No obvious change was observed on Bad;
(B) Bcl-2/Bax ratio was decreased significantly with the increasing
concentration of PTL; (C) Activation of caspase-9 and caspase-3 after
PTL treatment.
Liu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:108
http://www.jeccr.com/content/29/1/108
Page 5 of 7PTL effectively suppressed cancer cell movement. Data
mentioned above demonstrated PTL might be a novel
chemotherapeutic agent.
In order to explore the molecular mechanism of PTL-
induced apoptosis in BxPC-3 cell, several genes were
detected. Wang et al [20] demonstrated that combina-
tion therapy with PTL and arsenic trioxide inhibited the
growth of pancreatic cancer cells via the mitochondrial
pathway. Researches have reported that Bcl-2 family
members are associated with mitochondria-related
apoptosis [21,22]. As main members of Bcl-2 family, the
antiapoptotic gene Bcl-2 and proapoptotic gene Bax
were analyzed in most human cancers which played
important roles in tumorigenesis and development [23].
Bcl-2 and Bax localize at the outer membrane of mito-
chondrial. The balance between them prevents translo-
cation of cytochrome-c from the mitochondria and
determines the apoptosis resistance. Inhibition of Bcl-2
or induction of Bax breaks the balance between two
genes (as showed in Fig.5B), resulting in mitochondrial
dysfunction and cytochrome-c release [21,22].
Researches have demonstrated that several Bcl-2 family
members are regulated by NF-kB [24,25]. Promoter ana-
lysis showed Bcl-2 had multiple putative NF-kB binding
sites [26,27]. Meanwhile, inhibition of NF-kB depressed
Bcl-2 expression [28].
Caspases, a family of cysteine proteases, play a critical
role in the execution of apoptosis [29] which are modu-
lated by several upstream genes, especially cytochrome-c
[30]. Once cytochrome-c is released into cytoplasm, it
binds to the adaptor molecule, Apaf-1, and forms the
apoptosome that activates caspase-9. Activated caspase-9
cleaves and activates procaspase-3 [31]. In our study data
showed that Bcl-2 and procaspase-3 proteins were down-
regulated after PTL treatment with the Bax and caspase-
9 protein up-regulated. Mitochondrial involvement con-
tributing to the mechanism of PTL-induced apoptosis
included NF-kB-mediated Bcl-2 down-regulation and Bax
up-regulation, release of mitochondrial cytochrome-c to
the cytoplasm and activation of caspase-9 and caspase-3.
In summary, PTL might be a new agent which can
effectively inhibit proliferation, invasion and induce
apoptosis in pancreatic cancer. Although the molecular
mechanisms for the PTL-induced effect still need to be
clarified, our data showed that the Bcl-2 family mole-
cules and caspase cascade reaction may be involved.
Further studies in vivo should be designed to verify the
PTL-induced effect.
Conclusions
NF-kB inhibitor PTL may be an agent which can effec-
tive against pancreatic cancer, because they can effec-
tively inhibit cell proliferation, induce cell apoptosis and
suppress metastatic activity. Although the molecular
mechanism(s) for the PTL-induced cancer cell apoptosis
are poorly understood, the Bcl-2 family molecules and
caspase cascade reaction might be involved. Therefore,
NF-kB specific inhibitors include PTL may be applicable
to a chemotherapeutic strategy for pancreatic cancer.
But this possibility should be followed-up with further
comprehensive studies.
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